Nitin Agrawal Resigns as Alkem Laboratories CFO, Effective September 30

Drug maker Alkem Laboratories on Thursday said its Chief Financial Officer (CFO) and Key Managerial Personnel Nitin Agrawal has resigned from the company to pursue new professional opportunities.

According to a regulatory filing by the pharmaceutical company, Agrawal will step down from his position effective September 30, 2026. He will also cease to hold his senior management position with the company from the same date.

The company said Agrawal submitted his resignation letter on July 30, 2026, communicating his decision to move on from his current responsibilities.

In his resignation letter, Agrawal said he had decided to step down to pursue opportunities aligned with his long-term professional and personal growth.

Alkem Laboratories did not provide further details about Agrawal's next professional assignment or the company's plans for appointing his successor in the regulatory disclosure.

Agrawal's resignation comes as the pharmaceutical company continues its operations across various segments of the healthcare and drug industry. As CFO, he was responsible for overseeing the company's financial functions and was part of its senior management.

The company is required to make regulatory disclosures regarding changes involving key managerial personnel under applicable listing requirements. The Mumbai-based pharmaceutical company has a presence across several therapeutic areas and markets, with operations spanning India and international markets.

Agrawal's departure will mark a change in the company's senior financial leadership from the end of September. Further details regarding the appointment of a new CFO are expected to be disclosed by the company as and when a decision is taken.

The regulatory filing did not indicate any dispute or other specific reason for Agrawal's resignation beyond his stated intention to pursue new professional opportunities.

Alkem Laboratories' shares are listed on Indian stock exchanges, and developments involving senior management are disclosed to investors through regulatory filings in accordance with applicable requirements.